Genetic Signatures

31 DIRECTORS’ REPORT FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 9 1.2 Key management personnel 2.1 Directors’ Fees The following persons were key management personnel of Genetic Signatures Limited during the financial year: Non-executive directors Dr Nickolaos Samaras - Chairman Dr Anthony J Radford AO Dr Neil Gunn (appointed 6 April 2021) Executive directors Dr John R Melki - Managing Director & Chief Executive Officer Michael A Aicher - Executive Director, US Operations Other executives Peter L Manley - Chief Financial Officer/Company Secretary 2 NON-EXECUTIVE DIRECTOR REMUNERATION The current remuneration was increased for Directors in recognition of business growth and resulting extra time and commitment from Non-executive Directors. Fees are inclusive of committee fees. Board fees per annum Chairman $108,000 Non-executive director (Australian based) $60,000 Non-executive director (overseas) 60,000 (USD, EUR or GBP depending on location) Superannuation Superannuation contributions for Australian-based non-executive directors are in addition to the Board fees and are calculated at a rate of 9.5% of the base fee, as required under the statutory superannuation guarantee. Directors may elect to salary sacrifice additional payments to their fund. Share-based payments Non-executive directors are not entitled to any performance related remuneration but may receive option or equity grants if approved by shareholders. 2.2 Non-executive director remuneration Non-executive directors Year Cash salary and fees Super- annuation Share-based payments Total $ $ $ $ Nickolaos Samaras 2021 96,000 9,120 - 105,120 2020 60,000 5,700 - 65,700 Anthony J Radford 2021 56,250 5,344 - 61,594 2020 45,000 4,275 1,553 50,828 Neil Gunn 2021 19,479 - - 19,479 2020 - - - - Total 2021 171,729 14,464 - 186,193 2020 105,000 9,975 1,553 116,528 for the financial year ended 30 June 2021 DIRECTORS’ REPORT FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 9 1.2 Key management perso nel 2.1 Directors’ F es The following persons were key management perso nel of Genetic Signatures Limite during the financial year: Non-executive directors Dr Nickolaos Samaras - Chairman Dr Anthony J Radford AO Dr Neil Gu n (a pointed 6 April 2021) Executive directors Dr John R Melki - Managing Director & Chief Executive Officer Michael A Aicher - Executive Director, US Operations Other executives P ter L Manley - Chief Financial Officer/Company Secretary 2 NON-EXECUTIVE DIRECTOR REMUNERATION The current remuneration was increased for Directors in recogn tion of busine s growth and resulting extra time and co mitment from Non-executive Directors. F es are inclusive of co mitt e f es. Board f es per a num Chairman $108, 0 Non-executive director (Australian based) $60, 0 Non-executive director (overseas) 6 , 0 (USD, EUR or GBP depending on location) Supera nuation Supera nuation contributions for Australian-based non-executive directors are in a d tion to the Board f es and are calculated at a rate of 9.5% of the base f e, as required under the statutory supera nuation guarant e. Directors may elec to s lary sacr fice a d tional payments to their fund. Share-based payments Non-executive directors are not en itled to any performance related remuneration but may receive option or equity grants if a proved by shareholders. .2 Non-executive directo remuneration Non-executive directors Year Cash s lary and f es Super- a nuation Share-based payments Total $ $ $ $ Nickolaos Samaras 2021 96, 0 9,120 - 105,120 2020 6 , 0 5,7 0 - 65,7 0 Anthony J Radford 2021 56,250 5,3 4 - 61,594 2020 45, 0 4,275 1, 53 50,828 Neil Gu n 2021 19,479 - - 19,479 2020 - - - - Total 2021 171,729 1 ,464 - 186,193 2020 105, 0 ,975 1, 53 16,528